AstraZeneca reports positive data from Phase III trial of efzimfotase alfa

AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia ...

AstraZeneca scores pediatric win while adult trial falls short in rare bone disease

AstraZeneca Plc AZN released topline data from the Phase 3 program for efzimfotase alfa (ALXN1850) in the broad ...
COPD News Today

Tozorakimab reduces COPD exacerbations in two large clinical trials

The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with ...

AstraZeneca drug for rare bone disease shows positive trial results

A potential treatment developed by AstraZeneca for hypophosphatasia has showed positive results in phase III trials, the ...

AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results

The company said the results support the drug’s potential to transform the treatment of hypophosphatasia and it plans to submit data to regulators as soon as possible.
pharmaphorum

AZ considers filings for long-acting Strensiq follow-up

AstraZeneca's Alexion unit is planning to file a new, long-acting follow-up to its Strensiq therapy for ultra-rare disease ...
FiercePharma

AstraZeneca's Fasenra comes up short again in COPD as injectable Saphnelo makes grade in lupus

After another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat ...

AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard ...